Company / Interest Expense
Cytek Biosciences, Inc. Interest Expense History
FY2020-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Interest Expense
$2.1M
FY2023
5-year range
$333.0K / $2.6M
FY2020-FY2023
Trend
-19.5%
vs FY2022
Sector context
#41 of 44
Health Care
What the data says
Among 44 Health Care companies, Cytek Biosciences, Inc. is in the top 7% for interest expense. Increased from $333,000 to $2M over the past 2 years.
Based on SEC 10-K filings.
$2M in FY2023 with a 3-year CAGR of +83.9%.
Increased from $333,000 to $2M over the past 2 years.
Health Care sector context is included.
Interest Expense over time
Growth rates
- 3-Year CAGR
- +83.9%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 7% in Health CareTop 7% of 44This company $2.1M Sector average $316.9M
▼
-99.3% below sector average
Key checks
Key Insights
- 3-year CAGR of +83.9%, indicating consistent growth.
- In FY2023, interest expense decreased 19.5% year-over-year.
- Ranks #41 out of 44 companies in the Health Care sector.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Interest ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $2.1M | -19.5% |
| FY2022 | $2.6M | +672.7% |
| FY2021 | $333.0K | +0.0% |
| FY2020 | $333.0K | - |
As of FY2023 · SEC 10-K · Updated Jul 2, 2026